

Contents

Preface XVII

List of Contributors XIX

Part One Steroid Hormones

1	Glucocorticoids and Mineralocorticoids	3
	<i>Eilidh Craigie, John J. Mullins, and Matthew A. Bailey</i>	
1.1	Synthesis of the Corticosteroids	3
1.2	Regulation of Corticosteroid Synthesis	7
1.2.1	Aldosterone	7
1.2.2	Glucocorticoids	9
1.3	Corticosteroid Receptors and Control of Ligand Access	11
1.3.1	Steroid Receptors	11
1.3.2	Control of Ligand Access	12
1.3.2.1	11 β HSD1	13
1.3.2.2	11 β HSD2	14
1.4	Cardiovascular Effects of Aldosterone	16
1.4.1	Aldosterone and the Heart	16
1.4.2	Vasculature	19
1.5	Cardiovascular Effects of Glucocorticoids	21
1.5.1	Transgenic Models	23
1.5.2	Lessons from Human Disease	24
1.5.2.1	Cushing's Syndrome	24
1.5.2.2	The Metabolic Syndrome and Tissue-Specific Regulation of Glucocorticoids	25
1.5.2.3	Glucocorticoid Resistance Syndrome	25
1.5.2.4	GR Polymorphisms	26
1.5.3	Endothelial Dysfunction, Vascular Tone and Atherosclerosis	26
	References	27

2	Sex Steroid Hormones	39
	<i>Vera Regitz-Zagrosek, Eva Becher, Sebastian Brokat, Shokoufeh Mahmoodzadeh, and Carola Schubert</i>	
2.1	Sex Differences in Cardiovascular Physiology and Disease and Effect of Hormone Therapy	39
2.2	Sex Steroids: Estradiol, Estrone, Testosterone and Progesterone	40
2.2.1	Synthesis and Endocrine Physiology	40
2.2.2	Age-Dependent Blood Levels of Sex Hormones in Females and Males	40
2.2.3	Levels of Estradiol and Testosterone in Rodents	41
2.3	Sex Hormone Receptors: Structure and Function	41
2.3.1	Hormone Response Element	42
2.3.2	Molecular Mechanisms of Nuclear Receptor Activation	42
2.3.2.1	Ligand-Dependent Transcription	42
2.3.2.2	Ligand-Independent Genomic Pathway: Cross-Talk Between SHRs and Other Signal Transduction Pathways	42
2.3.2.3	Nongenomic Pathway	44
2.3.3	Role of Coregulators in Transcriptional Regulation by SHRs	44
2.3.4	Role of Proteasomal Degradation Pathway in SHR-Mediated Gene Transcription	44
2.3.5	Receptor Activity and Availability in the Cardiovascular System	45
2.3.6	Localization of SHRs in the Heart and Vessels of Rodent and Men	45
2.4	Receptor-Independent Effects of Sex Steroids	47
2.5	Sex Hormone Effects on Cardiovascular Cells and Organs	47
2.5.1	Sex Hormone Effects on Different Cardiovascular Cell Types	47
2.5.1.1	Cardiomyocytes	47
2.5.1.2	Fibroblasts	48
2.5.1.3	Endothelial Cells	48
2.5.1.4	Vascular Smooth Muscle Cells	48
2.5.1.5	Platelets	48
2.5.2	Sex Hormone Effects on the Heart	49
2.5.2.1	Effects of Exercise	49
2.5.2.2	Pressure Overload	50
2.5.2.3	Hypertension	50
2.5.2.4	Volume Overload	50
2.5.2.5	Myocardial Infarction	51
2.5.3	Sex Hormone Effects on Atherosclerosis, Plaque Formation and Rupture	51
2.5.4	Sex Hormone Effects on Systemic and Circulating Mediators of the Cardiovascular System	52
2.5.4.1	Lipid Levels	52
2.5.4.2	Glucose and Insulin	53
2.5.4.3	Blood Pressure	53
2.5.4.4	Coagulatory Activity	53
	References	54

Part Two Peptide Hormones

- 3 Angiotensins 67**
*Robson Augusto Souza Dos Santos, Anderson José Ferreira,
 and Ana Cristina Simões e Silva*
- 3.1 Introduction 67
- 3.2 RAS: The Classical and Updated View 67
- 3.3 New Aspects of Classical RAS Enzymes 68
- 3.3.1 Renin/Prorenin Receptor 68
- 3.3.2 Signaling Through ACE 68
- 3.4 Ang II 69
- 3.4.1 Ang II and the Cardiovascular System 72
- 3.4.2 Ang II and the Endocrine System 73
- 3.4.3 Ang II and the Renal System 74
- 3.5 Ang-(1-7) 77
- 3.5.1 Ang-(1-7) and the Heart 77
- 3.5.2 Ang-(1-7) and Blood Vessels 81
- 3.5.3 Ang-(1-7) and the Kidney 83
- 3.6 Ang III [Ang-(2-8)] 85
- 3.7 Ang IV/AT₄ Receptor Axis 85
- 3.8 Des-Asp¹-Ang I [Ang-(2-10)] 86
- 3.9 Other Angiotensin Peptides 87
- References 87
- 4 Kinins 101**
*Suzana Macedo de Oliveira, Kely de Picoli Souza, Michael Bader,
 and João Bosco Pesquero*
- 4.1 Introduction 101
- 4.2 Kininogens: Precursors of Kinins 103
- 4.3 Kinin-Forming Systems 104
- 4.4 Kininases 104
- 4.5 Kinin Receptors 106
- 4.6 Physiological and Pathological Cardiovascular Roles of Kinins 107
- 4.7 Kinins in Blood Pressure Control and Hypertension 109
- 4.8 Kinins in the Heart 110
- 4.9 Renal Effects of Kinins 112
- References 115
- 5 Natriuretic Peptides 125**
Paula M. Bryan and Lincoln R. Potter
- 5.1 History 125
- 5.2 Natriuretic Peptides: Structure, Processing and Expression 126
- 5.3 Natriuretic Peptide Receptors 126
- 5.3.1 NPR-A 128
- 5.3.2 NPR-B 130

5.3.3	NPR-C	131
5.4	Physiological Effects of the Natriuretic Peptide System	132
5.4.1	Effects on Blood Pressure	132
5.4.2	Effects of ANP/NPR-A on Intravascular Volume and Endothelium Permeability	133
5.4.3	Effects of ANP and BNP on Cardiac Hypertrophy and Fibrosis	133
5.4.4	Effects of ANP and CNP on Vascular Relaxation and Remodeling	133
5.4.5	Effects of ANP on Natriuresis and Diuresis	134
5.4.6	Natriuretic Peptides and Renal Function	134
5.5	Natriuretic Peptides as Diagnostic Indicators of Heart Failure	135
5.6	NPRs and Heart Failure	135
5.7	Therapeutic Applications and Future Directions	136
	References	136
6	Endothelins	143
	<i>Gian Paolo Rossi and Teresa M. Seccia</i>	
6.1	Endothelin System	143
6.2	ET and Cardiovascular Disease	145
6.3	Assessment of the ET System in Disease States	146
6.4	ET in PAH	148
6.5	ET in Systemic Arterial Hypertension	149
6.5.1	Animal Studies	149
6.5.2	Human Studies	151
6.5.3	ET-1 in Renal Disease	152
6.5.3.1	Blood Pressure, Proteinuria and ERAs	154
6.6	ERAs in Human Renal Diseases	154
6.7	ET and Heart Failure	155
6.8	Role of ET in Heart Failure	156
6.8.1	ET-1 Plasma Levels in Heart Failure	156
6.8.2	ERAs in Heart Failure	157
6.8.3	Selective or Nonselective ERAs in Heart Failure?	158
6.9	Long-Term Effects of ERAs in Heart Failure	159
6.10	Conclusions	160
	References	161
7	Adrenomedullin	169
	<i>István Szokodi and Heikki Ruskoaho</i>	
7.1	Molecular Aspects of AM	169
7.1.1	Structure and Synthesis of AM	169
7.1.2	Distribution and Sites of AM Production	170
7.1.3	Regulators of AM Gene Expression	170
7.1.4	AM Receptors	171
7.2	Functional Role of AM in the Heart	172
7.2.1	AM and Myocardial Contractility	172
7.2.1.1	Effect of AM on Cardiac Contractility	172

7.2.1.2	Signaling Mechanisms	172
7.2.2	AM and Coronary Blood Flow	173
7.2.2.1	Effect of AM on Coronary Vascular Tone	173
7.2.2.2	Signaling Mechanisms	175
7.2.3	AM in Myocardial Ischemia	176
7.2.3.1	AM Production in Myocardial Ischemia	176
7.2.3.2	Myocardial Cytoprotection by AM	177
7.2.3.3	Signaling Mechanisms	178
7.2.4	AM and Angiogenesis	179
7.2.4.1	Angiogenic Effect of AM	179
7.2.4.2	Signaling Mechanisms	180
7.2.5	AM in Heart Failure	180
7.2.5.1	Cardiac AM Production in Heart Failure	180
7.2.5.2	Acute Hemodynamic Effects of AM in Heart Failure	181
7.2.5.3	Chronic Effects of AM on Heart Failure Progression	182
	References	184
8	Apelin and Vasopressin	193
	<i>Xavier Iturrioz, Annabelle Reaux-Le Goazigo, Françoise Moos, and Catherine Llorens-Cortes</i>	
8.1	Discovery of Apelin	193
8.2	Structure and Processing of the Apelin Precursor	194
8.3	Apelin Receptor Signaling and Internalization	195
8.4	Distribution of Apelin and Its Receptor within the Adult Rat Brain	196
8.4.1	Topographical Distribution of Apelin	196
8.4.2	Distribution of Apelin Receptor mRNA Expression	197
8.5	Apelin: Physiological Actions within the Brain and Anterior Pituitary Gland	197
8.5.1	Involvement of Vasopressin and Apelin in the Maintenance of Water Balance	197
8.5.1.1	Vasopressinergic System	197
8.5.1.2	Apelinergic System	199
8.5.2	Apelin, like Vasopressin, is involved in Regulating the Hypothalamic–Adrenal–Pituitary Axis	202
8.6	Peripheral Cardiovascular Actions	203
8.7	Conclusions and Pathophysiological Implications	204
	References	205

Part Three Amines

- 9 Serotonin 211**
Michael Bader
- 9.1 Introduction 211
 - 9.2 Components of the Serotonin System 213
 - 9.2.1 Enzymes 213
 - 9.2.1.1 Tryptophan Hydroxylases 213
 - 9.2.1.2 Aromatic Amino Acid Decarboxylase 215
 - 9.2.1.3 Monoamine Oxidases 216
 - 9.2.2 Transporters 216
 - 9.2.2.1 Serotonin Transporter 216
 - 9.2.2.2 Vesicular Monoamine Transporters 217
 - 9.2.3 5-HT Receptors 217
 - 9.2.3.1 5-HT₁ Family 217
 - 9.2.3.2 5-HT₂ Family 218
 - 9.2.3.3 5-HT₃ Family 218
 - 9.2.3.4 5-HT₄ Family 218
 - 9.2.3.5 5-HT₅ Family 219
 - 9.2.3.6 5-HT₆ Family 219
 - 9.2.3.7 5-HT₇ Family 219
 - 9.3 Cardiovascular Actions 219
 - 9.3.1 Platelets 219
 - 9.3.2 Vessels 221
 - 9.3.3 Heart 222
 - 9.3.4 Brain 223
 - 9.4 Conclusions 225
 - References 225
- 10 Adrenaline and Noradrenaline 233**
Nadine Beetz and Lutz Hein
- 10.1 Introduction 233
 - 10.2 Biosynthesis and Degradation of Noradrenaline and Adrenaline 234
 - 10.2.1 Biosynthesis 234
 - 10.2.1.1 Tyrosine Hydroxylase (TH) 235
 - 10.2.1.2 Aromatic L-Amino Acid Decarboxylase (AADC) 235
 - 10.2.1.3 Dopamine β -Hydroxylase (DBH) 236
 - 10.2.1.4 Phenylethanolamine N-Methyltransferase (PNMT) 237
 - 10.2.2 Metabolism 238
 - 10.2.2.1 Noradrenaline Transporter (NET) 239
 - 10.2.2.2 Organic Cation Transporter 3 (OCT3) 240
 - 10.2.2.3 Catechol O-Methyltransferase (COMT) 240
 - 10.2.2.4 Monoamine Oxidase A (MAO-A) 240
 - 10.2.2.5 Vesicular Monoamine Transporter 2 (VMAT2) 241

10.3	Adrenergic Receptors	241
10.3.1	α_1 -Adrenoceptors	242
10.3.1.1	Mouse Models	242
10.3.1.2	Human Genetics and Function	242
10.3.2	α_2 -Adrenoceptors	243
10.3.2.1	Mouse Models	243
10.3.2.2	Human Genetics and Function	243
10.3.3	β -Adrenoceptors	244
10.3.3.1	Mouse Models	244
10.3.3.2	Human Genetics and Function	244
10.4	Conclusions	244
	References	245
11	Dopamine	251
	<i>Pedro Gomes and Patr�io Soares-da-Silva</i>	
11.1	Introduction	251
11.2	Dopamine Synthesis	251
11.2.1	L-DOPA Uptake and Decarboxylation	251
11.2.2	Amino Acid Transporters	252
11.2.3	Mechanisms Regulating Dopamine Availability	254
11.3	Dopamine Receptors	255
11.3.1	Classification	255
11.3.2	Tissue Distribution	257
11.4	Signaling Machinery and Effectors Downstream Dopamine Receptor Activation	257
11.4.1	Ion Transporters and Channels	257
11.4.2	G-Proteins	258
11.4.3	Adenylyl Cyclase/Protein Kinase A	259
11.4.4	Phospholipase C/Protein Kinase C	259
11.4.5	Other Pathways	260
11.5	Peripheral Effects of Dopamine	261
11.5.1	Renal Function	261
11.5.1.1	Renal Blood Flow	261
11.5.1.2	Glomerular Filtration Rate	261
11.5.1.3	Tubular Effect	262
11.5.2	Gastrointestinal Effect	263
11.6	Dopamine and Pathophysiology	263
11.6.1	Hypertension	263
11.6.2	Renal Failure	265
11.6.3	Heart Failure	266
11.6.4	Diabetes Mellitus	266
11.6.5	Aging	267
11.7	Clinical Applications of Dopamine	268
11.7.1	Heart Failure	268
11.7.2	Renal Failure	269

- 11.7.3 Surgery and Transplantation 271
- 11.7.4 Sepsis and Inflammation 274
- References 275

12 Histamine 295

Izabela Rozenberg, Felix C. Tanner, and Thomas F. Lüscher

- 12.1 Introduction 295
- 12.2 Biochemistry 296
 - 12.2.1 Synthesis 296
 - 12.2.2 Degradation 296
- 12.3 Receptors 297
- 12.4 Vasomotion 298
 - 12.4.1 EDRF 298
 - 12.4.1.1 Signaling Role of Ca²⁺ 300
 - 12.4.1.2 Activation of eNOS 300
 - 12.4.1.3 Transcriptional Regulation of eNOS 300
 - 12.4.2 EDCF 300
- 12.5 Thrombosis 301
 - 12.5.1 Tissue Factor Expression 301
 - 12.5.2 Weibel–Palade Bodies 303
 - 12.5.3 Platelet Aggregation 304
- 12.6 Inflammation 304
 - 12.6.1 Vascular Permeability 305
 - 12.6.2 Adhesion Molecule Expression 305
 - 12.6.3 Leukocyte Accumulation 306
 - 12.6.4 Regulation of T_h1/T_h2 Balance 306
 - 12.6.5 Macrophage Activation 307
 - 12.6.6 Obesity 307
- 12.7 Atherosclerosis 307
- 12.8 Autoimmune Diseases and Allergy 308
 - 12.8.1 Autoimmune Diseases 308
 - 12.8.2 Allergy 308
 - 12.8.2.1 Immediate Response 309
 - 12.8.2.2 Long-Term Response 309
- 12.9 Conclusions 310
- References 310

13 Prostaglandins and Leukotrienes 315

Katharina Lötzer and Andreas J. R. Habenicht

- 13.1 AA Metabolism by the COX and 5-LO Pathways 315
- 13.2 PGs in Cardiovascular Physiology and Pathophysiology 317
 - 13.2.1 Diversity of Prostanoid Effects in the Cardiovascular System 317
 - 13.2.2 PGs and Atherosclerosis 317
 - 13.2.3 COX-2 Inhibition and Cardiovascular Risk in Humans 319

- 13.3 LTs in Cardiovascular Physiology and Pathophysiology 320
 - 13.3.1 Activities of LTs in the Cardiovascular System 320
 - 13.3.2 5-LO Atherosclerosis Hypothesis 321
 - 13.3.3 5-LO Pathway in Mouse Models of Atherosclerosis 322
 - 13.3.4 Population Genetic Studies Indicate a Role of the 5-LO Pathway in Cardiovascular Disease 323
 - References 324

- 14 Cytochrome P450-Dependent Eicosanoids 333**
Wolf-Hagen Schunck and Cosima Schmidt
 - 14.1 Introduction 333
 - 14.2 Prospects of the Research Field 333
 - 14.3 How CYP Enzymes Became Established Members of the AA Cascade 335
 - 14.4 Structure and Function of CYP Enzymes and Their Role in AA Metabolism 336
 - 14.4.1 Unique Spectral and Catalytic Features of CYP Enzymes 336
 - 14.4.2 CYP Systems and Their Reaction Cycle in the ER 337
 - 14.4.2.1 Membrane Integration and Substrate Access 337
 - 14.4.2.2 Electron Transfer and Activation of Molecular Oxygen 337
 - 14.4.2.3 Product Formation and Specificity 337
 - 14.4.3 Reaction Types and Primary Products of CYP-Dependent AA Metabolism 339
 - 14.4.4 AA Metabolizing CYP Isoforms and Their Orthologs Among Rodents and Human 340
 - 14.4.4.1 CYP Superfamily 340
 - 14.4.4.2 Identity of AA-Metabolizing CYP Isoforms 340
 - 14.4.4.3 Problem of Overlapping Substrate Specificities 341
 - 14.4.4.4 Problem of Orthologous Genes 341
 - 14.5 Physiological and Pathophysiological Context of CYP-Dependent Eicosanoid Formation and Action 341
 - 14.5.1 Extracellular Signal-Induced AA Release 341
 - 14.5.2 Second Messenger Function 342
 - 14.5.3 Cellular Context and the Multiplicity of Signaling 342
 - 14.5.4 Physiological Context 342
 - 14.5.5 Role of I/R 342
 - 14.6 Systemic and Tissue-Specific Metabolic Factors Modulating CYP-Dependent Eicosanoid Formation 343
 - 14.6.1 Essential Fatty Acids Compete as Precursors for Oxygenated Metabolites 343
 - 14.6.1.1 ω -6 Fatty Acids 343
 - 14.6.1.2 ω -3 Fatty Acids 343
 - 14.6.1.3 Health Benefits from ω -3 Fatty Acids 345
 - 14.6.1.4 ω -3 Fatty Acids Are the Precursors of Novel CYP-Dependent Eicosanoids 345

- 14.6.2 Role of Nitric Oxide 345
- 14.6.3 Carbon Monoxide and Heme Oxygenase 346
- 14.6.4 CYP Enzymes as Targets, Sources and Utilizers of Reactive Oxygen Species 346
 - 14.6.4.1 Reactive Oxygen Species Affect CYP Activities 346
 - 14.6.4.2 Reactive Oxygen Species Production by CYP Enzymes 346
 - 14.6.4.3 CYP Enzymes Can Use Reactive Oxygen Species and Hydroperoxides for Substrate Oxygenation 346
- 14.7 Biological Activities of EETs and 20-HETE 347
 - 14.7.1 Regulation of Vascular Tone 347
 - 14.7.2 Regulation of Renal Tubular Function 347
 - 14.7.3 Cardiac Function 350
 - 14.7.4 General Cell- and Organ-Protective Properties of EETs 351
 - 14.7.5 Biological Activities of Eicosanoids Originating from CYP-Dependent *n*-3 PUFA Oxygenation 351
- 14.8 Secondary Product Formation and the Metabolic Fate of CYP-Dependent Eicosanoids 352
- 14.9 CYP-Dependent AA Metabolism in Animal Models of Hypertension and End-Organ Damage 353
 - 14.9.1 Prohypertensive and Proinflammatory Role of Vascular 20-HETE 355
 - 14.9.1.1 Androgen-Induced Hypertension 355
 - 14.9.1.2 Cyclosporin A-Induced Hypertension 355
 - 14.9.2 Antihypertensive Role of EETs in Salt-Sensitive Hypertension 355
 - 14.9.3 Antihypertensive Role of EETs in Pregnancy 356
 - 14.9.3.1 Renal and Vascular Alterations during Pregnancy 356
 - 14.9.3.2 Role of EETs in Placenta, Decidua and Trophoblasts 357
 - 14.9.4 20-HETE Deficiency and Salt-Sensitive Hypertension 357
 - 14.9.5 Role of EETs, HEETs and PPAR α in Inflammatory Renal Damage 357
- 14.10 Structure and Cardiovascular Functions of the Soluble Epoxide Hydrolase 358
 - 14.10.1 Enzymatic Activities 358
 - 14.10.2 sEH – A Novel Target for the Treatment of Cardiovascular Disease? 359
- 14.11 General Conclusions on Cause–Effect Relationships Associating Alterations in CYP-Dependent Eicosanoid Production and Cardiovascular Disease 359
 - 14.11.1 Any Alteration in CYP-Dependent AA Metabolism May Contribute to Cardiovascular Disease 359
 - 14.11.2 EET and 20-HETE Availability – A Bottleneck of Various Signaling Pathways? 360
 - 14.11.3 Is There a Primary Role of CYP-Dependent Eicosanoids and of CYP Gene Polymorphism in the Development of Cardiovascular Disease? 360

14.11.4	What Is the Cause for Alterations in the Production and Effects of CYP-Dependent Eicosanoids in Disease States?	361
	References	362
15	Nucleotides and the Purinergic System	373
	<i>Vera Jankowski and Joachim Jankowski</i>	
15.1	Introduction	373
15.2	Mononucleoside Polyphosphates	373
15.3	Dinucleoside Polyphosphates	375
15.4	Purinoceptor System	380
15.5	Metabolism of Nucleotides	383
15.6	Therapeutic Aspects of the Purinergic System	383
	References	384
16	Nitric Oxide	395
	<i>Valérie B. Schini-Kerth and Paul M. Vanhoutte</i>	
16.1	Regulation of the Endothelial Formation of NO	396
16.1.1	Hemodynamic Forces	396
16.1.2	Blood- and Platelet-Derived Factors	398
16.1.3	Local and Circulating Hormones, Growth Factors, and Neurotransmitters	399
16.1.4	Polyphenols	400
16.2	Vasoprotective Effects of NO	400
16.2.1	Regulation of Vascular Tone and Structure	400
16.2.2	Regulation of Coagulant and Thrombotic Responses	402
16.2.3	Regulation of Atherogenic Responses	402
16.3	Conclusions	403
	References	403
17	Acetylcholine	407
	<i>Maria Cláudia Irigoyen, Catarina S. Porto, Pedro Paulo Soares, Fernanda Consolin-Colombo, and Antônio Cláudio Nóbrega</i>	
17.1	Muscarinic Acetylcholine Receptor: Subtypes and Intracellular Signaling	407
17.1.1	Muscarinic Receptors in the Heart	409
17.2	Physiological Effects of ACh on the Heart	410
17.2.1	Reflex Control of Heart Rate by the Autonomic Nervous System	411
17.3	Parasympathetic Dysfunction: Clinical Impact on the Cardiovascular System	414
17.4	ACh and Vascular Function	417
	References	418
	Index	425